Antioxidant Carbocysteine Treatment in Obstructive Sleep Apnea Syndrome: A Randomized Clinical Trial

Kang Wu, Xiaofen Su, Guihua Li, Nuofu Zhang*

Guangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Diseases, The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

* nfzhanggird@163.com

Abstract

Objective

This study aimed to examine the effects of carbocysteine in OSAS patients.

Methods

A total of 40 patients with moderate to severe obstructive sleep apnea syndrome (OSAS) were randomly divided into two groups. One group was treated with 1500 mg carbocysteine daily, and the other was treated with continuous positive airway pressure (CPAP) at night. Before treatment and after 6 weeks of treatment, all patients underwent polysomnography and completed questionnaires. Treatment compliance was compared between the two groups. Plasma was collected for various biochemical analyses. Endothelial function was assessed with ultrasound in the carbocysteine group.

Results

The proportion of patients who fulfilled the criteria for good compliance was higher in the carbocysteine group (n = 17) than in the CPAP group (n = 11; 100% vs. 64.7%). Compared with baseline values, the carbocysteine group showed significant improvement in their Epworth Sleepiness Scale score (10.18±4.28 vs. 6.82±3.66; P≤0.01), apnea-hypopnea index (55.34±25.03 vs. 47.56±27.32; P≤0.01), time and percentage of 90% oxygen desaturation (12.66 (2.81; 50.01) vs. 8.9 (1.41; 39.71); P≤0.01), and lowest oxygen saturation level (65.88±14.86 vs. 70.41±14.34; P≤0.01). Similar changes were also observed in the CPAP group. The CPAP group also showed a decreased oxygen desaturation index and a significant increase in the mean oxygen saturation after treatment, but these increases were not observed in the carbocysteine group. Snoring volume parameters, such as the power spectral density, were significantly reduced in both groups after the treatments. The plasma malondialdehyde level decreased and the superoxide dismutase and nitric oxide levels increased in both groups. The endothelin-1 level decreased in the CPAP group but did not significantly change in the carbocysteine group. Ultrasonography showed that the

intima-media thickness decreased (0.71±0.15 vs. 0.66±0.15; P≤0.05) but that flow-mediated dilation did not significantly change in the carbocysteine group.

Conclusions

Oral carbocysteine slightly improves sleep disorders by attenuating oxidative stress in patients with moderate to severe OSAS. Carbocysteine may have a role in the treatment of OSAS patients with poor compliance with CPAP treatment. However, the efficiency and feasibility of carbocysteine treatment for OSAS needs further evaluation.

Trial Registration

ClinicalTrials.gov NCT02015598

Introduction

Obstructive sleep apnea syndrome (OSAS) is characterized by repeated episodes of upper airway occlusion during sleep and excessive daytime sleepiness (EDS). It affects at least 4% of adult men and 2% of adult women [1]. OSAS has been identified as having a causal association with cardiovascular disease [2]. Continuous positive airway pressure (CPAP) is currently recognized as the first-line treatment for OSAS. However, poor compliance with CPAP treatment is very common, often because of the cost of CPAP devices and the discomfort associated with their use. Although CPAP can improve symptoms and reduce complications [3, 4], the failure rate of CPAP treatment exceeds 50% [5]. Therefore, there is an urgent need for alternative OSAS treatments.

Because OSAS causes repeated cycles of hypoxia and re-oxygenation that resemble ischemia-reperfusion, the production of reactive oxygen species (ROS) can result from excessive mitochondrial reduction during hypoxia [6]. Several studies have proposed that oxidative stress could underlie the association between OSAS and cardiovascular diseases [7]. Some studies have even reported that OSAS is an oxidative stress disease [8]. Good compliance with CPAP treatment can reduce several cardiovascular risk factors in OSAS patients [4]; however, some studies have shown that CPAP cannot completely repair the oxidant-antioxidant imbalance [9, 10]. Interestingly, antioxidants, such as vitamin C, vitamin E, allopurinol and N-acetyl-cysteine (NAC), have been shown to positively affect OSAS [11–14]. However, these studies had limitations; for example, most of them enrolled a small number of subjects, and few compared polysomnographic (PSG) parameters, which are important in evaluation of OSAS, before and after treatment. In addition, few reports have compared the outcomes of CPAP use and antioxidant treatments.

Thus, we aimed to identify an antioxidant that is at least as beneficial as previously identified agents for the treatment of OSAS. Carbocysteine could be functionally more effective than some of the other antioxidants currently in use because it scavenges free radicals and replenishes glutathione (GSH), which is a major contributor to antioxidant capacity [15, 16]. In addition, it is less expensive than other antioxidants, including double antioxidant capacity drugs such as NAC. The PEACE study, which was conducted at our institution, found that carbocysteine can be effectively used to treat chronic obstructive pulmonary disease patients. Specifically, carbocysteine reduces exacerbations of the disease and improves quality of life by alleviating oxidative stress and inflammation [17]. Our study was undertaken to evaluate

whether the oral antioxidant carbocysteine can effectively reduce oxidative stress and sleep disordered breathing (SDB) in OSAS. This treatment could improve SDB and correct the oxidant-antioxidant imbalance, and it could reduce cardiovascular complications in OSAS patients. Our results indicate that oral carbocysteine has therapeutic potential for patients with moderate to severe OSAS.

Methods

### 1. Ethics, Study Subjects and Protocol

The study was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University (project approval number 2013–19) and was performed according to its guidelines. All of the subjects provided informed written consent. The clinical trial registration number was NCT02015598. Grant support was received from the Science and Technology Planning Project of Guangdong Province, China (2008B03031254). The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Subjects were included in the study if they were (1) men aged 18 to 65 years old; (2) diagnosed with obstructive sleep apnea with an apnea-hypopnea index (AHI) $\geq$15 /h based on the PSG data; (3) non-smokers or had quit smoking $\geq$6 months prior; and (4) were able to provide consent. Subjects were excluded if they (1) could not tolerate carbocysteine or CPAP; (2) had a history of treatment for OSAS; (3) had an active acute or chronic infection; (4) had been diagnosed with a cardiovascular, neuromuscular, peripheral vascular, or chronic respiratory disease; (5) used steroidal, nonsteroidal anti-inflammatory, or lipid-lowering drugs, vasodilators, cardiovascular medications, or other medications that lower oxidative stress; or (6) used drugs that impair sleep.

Our study enrolled 40 patients with moderate to severe OSAS diagnosed based on overnight PSG studies conducted at a sleep laboratory at the Guangzhou Institute of Respiratory Diseases in Guangzhou, China, from December 2013 to May 2014. The participants were randomly assigned (1:1) to 1 of 2 treatment groups, the carbocysteine group (500 mg oral tablets t.i.d.; Baiyunshan Pharmaceutical, Guangzhou, Guangdong, China) or the CPAP (System One REMstar Auto 557P, Respironics, USA) group, according to simple randomization procedures (using computer-generated random numbers). Blood samples were collected from the participants between 7 and 9 a.m. We also used questionnaires to collect information about patient characteristics, including subjective daytime sleepiness. In addition, the patients in the carbocysteine group underwent endothelial function tests using ultrasonography between 4 and 5 p.m. All of the experimental evaluations were repeated 6 weeks after the CPAP or carbocysteine intervention for all patients. The patients did not use a CPAP device or take oral carbocysteine on the day of PSG monitoring (Fig 1).

2. Sleep Studies

The participants were required to complete questionnaires, and their daytime sleepiness was confirmed with the Epworth Sleepiness Scale (ESS)[18] before PSG monitoring began. The PSG monitoring (Alice 5 Diagnostic Device, Respironics, USA) included electro-encephalography (EEG), electro-oculography, electromyography, and electrocardiography and assessments of oronasal flow (thermistor), thoracoabdominal movements, body position, arterial oxygen saturation, and snoring sounds. Skilled staff manually analyzed and scored the electronic raw data according to the standard criteria. Apnea was defined as a significant decrease ($>$90%) in oronasal flow compared with the baseline for at least 10 seconds. At least 90% of the event's duration had to meet the amplitude reduction criteria. Hypopnea was defined as an airflow

```
                    ┌─────────────────────┐
                    │   PSG monitoring    │
                    │     AHI>15/h        │
                    └─────────────────────┘
            ┌──────────────────┴──────────────────┐
    ┌───────────────────┐              ┌───────────────────┐
    │   CPAP device     │              │   Carbocysteine   │
    │   During sleep    │              │  500 mg oral t.i.d│
    └───────────────────┘              └───────────────────┘
```

CPAP device During sleep	Carbocysteine 500 mg oral t.i.d
Plasma Oxidative Stress Assay Plasma Endothelial Function Assay PSG parameters	Plasma Oxidative Stress Assay Plasma Endothelial Function Assay PSG parameters Ultrasound Imaging Study

6 weeks Therapy

PSG monitoring Not use CPAP device	PSG monitoring
Plasma Oxidative Stress Assay Plasma Endothelial Function Assay PSG parameters Compliance Evaluation	Plasma Oxidative Stress Assay Plasma Endothelial Function Assay PSG parameters Ultrasound Imaging Study Compliance Evaluation

Fig 1. Study plan. PSG = Polysomnography; CPAP = continuous positive airway pressure; t.i.d. = three times a day.

decrease of ≥30% compared with the baseline for at least 10 seconds with ≥4% desaturation from the baseline, or a decrease of ≥50% from the baseline for at least 10 seconds with ≥3% desaturation from the baseline and/or arousal. At least 90% of the event's duration had to meet the criteria for hypopnea. An oxygen desaturation event was defined as a ≥3% decrease in oxygen. The AHI was defined as the total number of apnea and hypopnea events per hour throughout the total sleep time. According to the American Academy of Sleep Medicine, OSAS severity was based on the AHI and was graded as mild ($5 \leq AHI \leq 15$ /h), moderate ($15 < AHI \leq 30$, n/h), or severe ($AHI > 30$, n/h).

Snoring sounds were monitored simultaneously with the PSG parameters using a piezoelectric snore sensor. The sensor was placed over the suprasternal notch of the trachea to detect the location of the strongest vibrations. The location was marked using adhesive tape. The sound signals were amplified and filtered using a band-pass filter with a frequency range of 70–2000 Hz (to remove the effects of environmental sounds and vascular pulsation noises), a digitized

sampling rate frequency of 5000 Hz and a 12-bit A/D converter. All of the snoring episodes were identified by the same analyzer, who rejected other sounds, such as coughing and talking. The analyzer randomly selected 10 stable and regular snoring sound segments for each subject during the full-night PSG study. The mean value of the 10 samples was then used for analysis. A snore contains a range of energy called the power spectral density (PSD). The characteristics of PSD can be used to determine different parameters [19], including the mean (Fmean), median (Fmed), maximum (Fmax), and peak frequencies (Fpeak), with the latter defined as the upper limit of the 95th percentile of the PSD energy frequencies.

3. Compliance Evaluation

All of the participants were contacted weekly by telephone to inquire about potential side effects and ensure compliance. Compliance was evaluated at the end of the treatment period. In the carbocysteine group, the medication bottle was retrieved, and the number of remaining pills was counted. Good compliance was defined as a medication usage rate of ≥80%. In the CPAP group, the CPAP device's memory was downloaded at the end of the study. The CPAP usage and mean AHI data were obtained from data cards inside the CPAP machines. CPAP compliance was defined by the percentage of study days with ≥4 h of CPAP use and an AHI of ≤5/h. The subjects who used the CPAP machine on >70% of the study days were defined as having good compliance.

4. Biochemical Analyses

Fasting blood samples were drawn by venipuncture in the morning immediately after PSG and were collected in EDTA-containing tubes. The blood samples were centrifuged and frozen at -80°C until the biochemical analyses.

5. Plasma Oxidative Stress Assay

The plasma lipid peroxide levels were estimated using an improved analysis of thiobarbituric acid reactive substance assay, which is primarily performed to measure the malondialdehyde (MDA) level in a sample. Superoxide dismutase (SOD) enzymatic activity was measured using the xanthine oxidase technique. The total GSH concentrations were estimated using an enzyme-labeled immunosorbent assay (ELISA). The biochemical parameters were measured in duplicate, and the mean value was used in analyses. Kits for analyzing MDA, SOD, and GSH were acquired from the Nanjing Jiancheng Bioengineering Institute (Nanjing, China).

6. Plasma Endothelial Function Assay

The plasma levels of nitric oxide (NO) compounds (NO_x; NO_2^-; and NO_3^-) were measured using the nitric acid deoxidize enzyme method. The endothelin-1 (ET-1) level was measured using ELISA. Kits for analyzing the NO and ET-1 levels were acquired from Nanjing Jiancheng Bioengineering Institute (Nanjing, China).

7. Ultrasound Imaging Study

Ultrasound imaging studies were performed using ultrasonography (iU22 xMATRIX Ultrasound System, Philips, USA) for only the carbocysteine group. All measurements were performed at 4 p.m. on the day the PSG study was completed. The patients were examined in a quiet room after a 15-min resting period. A blood pressure cuff was placed 5 cm below the right antecubital fossa. The brachial artery was imaged above the right antecubital fossa in the longitudinal plane using high-resolution ultrasonography to establish the baseline condition.

Thereafter, an arterial occlusion was created by inflating a pneumatic blood pressure cuff until the systolic blood pressure was 50 mmHg greater than the baseline pressure for 5 min. This step was followed by rapid deflation of the cuff to increase blood flow through the brachial artery. The brachial artery diameter was measured again 1 min after cuff deflation to define the maximum condition. The absolute change in diameter was defined as the difference in the maximum and baseline diameters. The percentage of flow-mediated dilation (FMD) was calculated as follows: (absolute change/baseline)*100% [20].

The intima-media thickness (IMT) was measured [21] after FMD. Then, the subject rested again for 15 min. With the patient in the supine position, an ultrasound probe was applied longitudinally to the right side of the neck. The measurement was conducted at the far wall of the right carotid artery. Longitudinal scanning was performed from the common carotid artery to the bifurcation of the common carotid artery. IMT was measured within 10 mm proximal to the bifurcation using electronic calipers. Three points were measured in a single scan, and these measurements were synchronized with the R-wave peaks on ECG. Each subject was scanned three times. The mean IMT was calculated based on these nine points. The same experienced investigator, who was blinded to the statuses of the individual patients, performed all of the measurements.

8. Outcome Measures

The primary outcome objective was to demonstrate changes in the PSG parameters and oxidative stress biomarkers after 6 weeks of oral carbocysteine intake. The PSG parameters included the ESS score, AHI, T90%, $MSaO_2$, $LSaO_2$, and snoring parameters. The oxidative stress biomarkers included SOD and MDA.

The secondary outcome objective was to demonstrate the efficacy of oral antioxidant carbocysteine compared with CPAP treatment. An additional secondary endpoint was the change in vascular endothelial function after oral carbocysteine intake. Vascular endothelial function, including FMD and IMT, was measured using high-resolution ultrasonography at baseline and at 6 weeks after carbocysteine treatment.

9. Statistical Analysis

The results are presented as the mean±SEM or as the median and 25th and 75th percentiles unless otherwise indicated. The mean differences within and between groups were assessed using the paired and unpaired t-tests, respectively. Differences within and between groups in skewed variables were analyzed using the Mann-Whitney two-sample rank test and Wilcoxon's signed rank test, respectively. Correlations were assessed with Pearson's or Spearman's correlation analysis, as appropriate for normally distributed or skewed variables, respectively. The chi square test was used to compare categorical variables. Fisher's exact test was used if the assumptions of the chi square test were not appropriate. The tests were considered significant at $P<0.05$. Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) for Windows (SPSS, version 13.0).

Results

The 40 patients were randomly divided into two groups of equal size, the carbocysteine group and CPAP group. The characteristics of all subjects are shown in Table 1. Both groups included 3 subjects who were lost to follow-up. In the carbocysteine group, two subjects were withdrawn because they did not show up after three reminders, and one subject was excluded because he reported adverse effects (abdominal pain). In the CPAP group, one patient demanded another

Table 1. Characteristics of the study subjects. ESS = Epworth sleeping scale, AHI = Apnea-hypopnea index, ODI = Oxygen desaturation index, MSaO2 = Mean oxygen saturation, LSaO2 = Lowest oxygen saturation, T90% = Time percentage of 90% oxygen desaturation, Fpeak = Peak frequency. Data are given as means±SEM unless otherwise indicated

Variable	Carbocysteine group (n = 20)	CPAP group(n = 20)	P
Age	42.45±12.16	44.45±9.85	0.571
Neck circumference (cm)	40.88±2.92	39.68±1.59	0.115
Waist circumference (cm)	98.15±10.80	98.60±7.97	0.882
Body mass index (kg/m^2)	28.31±4.13	27.35±2.16	0.361
ESS	10.60±4.11	10.25±3.78	0.781
AHI(n/h)	51.82±24.98	50.16±19.25	0.815
ODI(n/h)	54.53±26.22	51.88±20.79	0.726
MSaO$_2$(%)	94.5 (89;96)	93(92;94.75)	0.346
LSaO$_2$(%)	67.45±14.33	69.95±12.19	0.556
T90%	10.23(2.48;43.88)	11.47 (5.02;24.68)	0.946

doi:10.1371/journal.pone.0148519.t001

treatment, and two patients experienced nasal discomfort while using the CPAP machine. Thus, only 17 patients completed the study in each group (Fig 2).

1. Compliance Evaluation and Patient Characteristics

The number of remaining pills and the data downloaded from the CPAP device memory indicated that all 17 subjects in the carbocysteine group and 11 subjects in the CPAP group had good compliance. The compliance significantly differed between the two treatments (100% versus 64.6%; P<0.05).

2. PSG Parameters

The ESS score, respiratory parameters, and snoring parameters are shown in Table 2. Both CPAP therapy and carbocysteine treatment significantly reduced the ESS score, AHI, T90%, Fpeak, Fmax, Fmed, and Fmean and increased the LSaO$_2$ compared with the baseline values (P<0.05, Table 2). However, the oxygen desaturation index (ODI) decreased and the MSaO$_2$ increased significantly in the CPAP group (P<0.05, Table 2). This response was not evident in the carbocysteine group (P>0.05, Table 2).

3. Plasma Oxidative Stress Parameters

The MDA levels significantly decreased and the SOD activity levels significantly increased compared with the baseline values in both groups (P<0.05, Table 3). We did not detect a significant difference in the GSH level in either group compared with the baseline level (P>0.05, Table 3).

4. Plasma Endothelial Function Parameters

Both the CPAP and carbocysteine treatments significantly increased the NO levels (P<0.05, Table 3). However, the ET-1 level was only significantly decreased in the CPAP group (P<0.05, Table 3), and it showed a non-significant change in the carbocysteine group (P>0.05, Table 3).

Enrollment

Assessed for eligibility (n= 57)

Excluded (n=17)
- ◆ Not meeting inclusion criteria (n= 10)
- ◆ Declined to participate (n=7)
- ◆ Other reasons (n=0)

Randomized (n=40)

Allocation

Carbocysteine group
Allocated to intervention (n= 20)
- ◆ Received allocated intervention (n=20)
- ◆ Did not receive allocated intervention (n= 0)

CPAP group
Allocated to intervention (n= 20)
- ◆ Received allocated intervention (n=20)
- ◆ Did not receive allocated intervention (n= 0)

Follow-Up

Lost to follow-up (give reasons) (n=2)

Two patients did not show up after three reminders.

Discontinued intervention (give reasons) (n=1)

One patient had adverse events of celialgia

Lost to follow-up (n=1)

One patient wanted another treatment.

Discontinued intervention (n=2)

Two patients felt their nasal discomfort.

Analysis

Analysed (n=17)
- ◆ Excluded from analysis (n=0)

Analysed (n=11)
- ◆ Excluded from analysis (n=6)
Six patients did not meet good compliance

Fig 2. Consort diagram. OSAS = sleep apnea syndrome; CPAP = continuous positive airway pressure.

doi:10.1371/journal.pone.0148519.g002

5. Ultrasound Imaging Study

Carbocysteine therapy significantly affected IMT (P<0.05, Fig 3A). FMD was slightly increased after carbocysteine treatment, but this increase was not significant (P = 0.182, Fig 3B). The baseline IMT was significantly correlated with $LSaO_2$ (r = -0.635, P = 0.006), $MSaO_2$ (r = -0.582, P = 0.014), T90% (r = -0.548, P = 0.023), and the NO level (r = -0.633, P = 0.006; Fig 4) but not with the AHI, ODI, or SOD activity or the MDA, GSH, or ET-1 levels. FMD was also not correlated with any of the above parameters.

Table 2. Polysomnography parameters in patients with OSAS before and after treatment. No significant difference of the baseline and the after treatment value between carbocysteine group and CPAP group.

Variable	Carbocysteine group (n = 17)			CPAP group (n = 11)		
	Baseline	After Carbocysteine	P	Baseline	After CPAP#	P
ESS	10.18±4.28	6.82±3.66	≤0.001	11.00±3.32	5.00±3.22	0.003
AHI (n/h)	55.34±25.03	47.56±27.32	0.008	54.44±21.52	42.17±19.53	0.002
ODI (n/h)	57.95±26.63	53.31±30.06	0.112	56.52±22.87	44.48±21.52	0.003
MSaO$_2$ (%)	94(89;96)	95(90,96)	0.143	93(91;95)	94(93,95)	0.027
LSaO$_2$ (%)	65.88±14.86	70.41±14.34	0.009	67.36±14.53	73.55±9.70	0.007
T90%	12.66 (2.81;50.01)	8.9 (1.41;39.71)	0.004	14.7 (6.31;37.86)	8.76 (3.87;15.99)	0.012
Fpeak	70.33±30.48	59.03±32.43	0.005	73.71±21.71	55.71±25.56	≤0.001
Fmax	54.53±29.41	42.76±28.09	≤0.001	52.07±23.56	38.98±23.42	0.003
Fmed	20.95±12.67	14.78±9.45	≤0.001	19.13±9.60	13.89±8.31	0.009
Fmean	16.20±10.13	10.53±6.38	≤0.001	14.41±7.74	10.26±5.80	0.028

the patients of CPAP group did not use CPAP when monitoring PSG. OSAS = Obstructive sleep apnoea syndrome, CPAP = Continuous positive airway pressure, Fmax = Maximum frequency, Fmed = Median frequency, Fmean = Mean frequency. The Fpeak, Fmax, Fmed and Fmean measures as snoring characteristics of power spectral density energy frequencies. Data are given as means±SEM or median (25th, 75th percentiles)

doi:10.1371/journal.pone.0148519.t002

Discussion

This study showed that OSAS patients who were treated with 1500 mg daily of the oral antioxidant carbocysteine (1) complied better with the treatment than those who were treated with CPAP. Furthermore, (2) carbocysteine significantly improved respiratory parameters and snoring characteristics, (3) reduced oxidative stress, and (4) improved endothelial function.

The upper airways of OSAS patients are narrowed or collapsed, and sleep state-dependent reductions in upper airway dilator motor neuron activity result in repeated episodes of airway occlusion [22]. These recurrent episodes cause short, repetitive cycles of hypoxia-reoxygenation that are associated with increased vascular production of ROS, which promotes oxidative stress. Oxidative stress can affect the tone of upper airway muscles by inhibiting hypoglossal neural output [23], and it can also impair upper airway respiratory muscles [24] and cause soft tissue edema in the upper airway [25]. These conditions can aggravate airway occlusion and create a vicious cycle in OSAS patients. In addition, oxidative stress contributes to impaired endothelial function in these patients [26]. According to previous research, antioxidants can reduce the symptoms of and ameliorate endothelial dysfunction in OSAS. Carbocysteine is a

Table 3. Plasma biochemical parameters in patients with OSAS before and after treatment. No significant difference of the baseline and the after treatment value between carbocysteine group and CPAP group.

Variable	Carbocysteine group (n = 17)			CPAP group (n = 11)		
	Baseline	After Carbocysteine	P	Baseline	After CPAP#	P
MDA (mmol/ml)	5.42±1.64	4.10±1.52	0.023	5.54±1.07	4.14±0.73	≤0.001
SOD (U/ml)	106.24±16.55	118.44±15.10	0.040	108.07±27.68	129.08±18.40	0.015
GSH (μmol/L)	38.66±7.93	40.52±43.91	0.437	39.11±6.79	44.36±8.817	0.141
NO (μmol/L)	33.74±12.18	40.36±10.08	0.047	33.37±17.42	43.91±15.73	0.012
ET-1 (pg/ml)	43.22±3.54	42.27±3.63	0.373	44.17±5.35	40.04±2.67	0.015

the patients of CPAP group did not use CPAP when monitoring PSG. OSAS = Obstructive sleep apnoea syndrome, CPAP = Continuous positive airway pressure, MDA = Malondialdehyde, SOD = Superoxide dismutase, GSH = Glutathione, NO = Nitric oxide, ET-1 = Endothelin-1.

doi:10.1371/journal.pone.0148519.t003

Fig 3. Ultrasound imaging study at baseline and after treatment in the carbocysteine group. (A)Flow-mediated dilation (FMD) of the brachial artery at baseline and after Carbocysteine of 1.5 g daily for 6 weeks in the obstructive sleep apnea group (n = 17; 8.38±4.95 vs. 10.06±5.78; P = 0.182). (B) Intima-media thickness (IMT) of the brachial artery at baseline and after Carbocysteine of 1.5g daily for 6 weeks in the obstructive sleep apnea group (n = 17; 0.71 ± 0.15 vs. 0.66 ± 0.15; P = 0.034)

doi:10.1371/journal.pone.0148519.g003

muco-active drug with *in vitro* free radical scavenging and anti-inflammatory properties [16]. It is widely used to treat COPD, pneumonia, rhinitis, and other disorders. However, its use to treat OSAS has not been reported.

Oral carbocysteine is not only convenient, it is also safe and inexpensive. Our study showed that only one of the twenty patients in the carbocysteine group experienced an adverse event (slight abdominal pain). The symptoms abated once this patient stopped taking the medicine. The PEACE study showed that the nature and incidence of adverse events are similar between carbocysteine- and placebo-treated subjects at 1 year [17]. These results indicate that the long-term use of carbocysteine is well tolerated. The commonly used definition of adequate CPAP compliance is ≥4 h of usage per night. This definition is not completely satisfactory because a significant proportion of patients likely require >4 h of usage per night for maximal benefit [27]. OSAS results in respiratory events when patients do not use a CPAP machine. If good

Fig 4. Correlation between intima-media thickness (IMT) and PSG Parameters in OSAS patients at baseline. (A) Pearson correlation analysis between lowest oxygen saturation (LSaO$_2$) and baseline IMT. (B) Spearman correlation analysis between Mean oxygen saturation (MSaO2) and baseline IMT. (C) Spearman correlation analysis between time percentage of 90% oxygen desaturation (T90%) and baseline IMT. (D) Spearman correlation analysis between nitric oxide (NO) and baseline IMT.

doi:10.1371/journal.pone.0148519.g004

compliance had been defined by the overnight use of a CPAP machine, then even fewer patients in the CPAP group would have been considered to have good compliance.

Interestingly, the OSAS patients reported that their snoring was relieved after one or two weeks of treatment with carbocysteine. This finding is similar to those of a previous study, in which NAC was able to decrease snoring, relative snoring time, snoring episodes, and the duration of the longest snoring episodes [14]. However, the volume of snoring that disturbs others has not yet been investigated. Although snore detection is a useful method for monitoring snoring [28], a full-night PSG study can also record snoring volume data using a piezoelectric snore sensor, which is not affected by surrounding noises. This sensor cannot determine the actual number of decibels, but it can be used to semi-quantitatively analyze the data obtained from a self-controlled study. The sound spectrum, which occurs in cycles, might aid in the identification of the acoustics of snoring according to the following properties: (1) the interval and amplitude of snoring are almost identical to and consistent with the breathing rate; (2) the impulse wave of snoring is more regular and periodic than that of the voice; and (3) the short-term energy of snoring is greater than that of the normal voice and is evenly distributed throughout the night [29]. These characteristics could help to discern snoring from other sounds, such as speaking, stridor, and wheezing. In our study, we found that the carbocysteine and CPAP treatments significantly reduced the snoring volume measurements, including the Fpeak, Fmax, Fmed, and Fmean. An increase in snoring volume causes increases in pharyngeal tissue vibration and airflow turbulence, which are relieved with treatment. Snoring is a public health problem that can negatively affect OSAS patients and the people around them, and snoring volume should be considered. However, snore detection is costly and cannot be widely used. Furthermore, the analysis of snoring sounds has not been standardized and lacks guidelines. Viable and simple snoring parameters extracted from PSG data may be used to analyze the changes in self-controlled or semi-quantitative studies. To our knowledge, this study is the first self-controlled study to investigate snoring sounds using only PSG data.

CPAP, the most widely used and effective therapeutic intervention for OSAS patients, improved the PSG parameters and EDS scores in our patient cohort. The antioxidant carbocysteine produced similar effects, except for the changes in the ODI and $MSaO_2$. These findings demonstrate that CPAP is superior to oral carbocysteine. However, the carbocysteine group did not show clinically relevant changes in the PSG parameters. In addition, the subjects in the CPAP group did not exhibit clinically significant changes in these parameters when they were studied at night without CPAP; under those circumstances, these patients remained in the severe OSA spectrum. Oxidative stress decreased in both groups after treatment. However, the GSH level did not change after the interventions in either group. Because GSH is an antioxidant enzyme that fights enzymatic oxidation, it may be easily oxidized in OSAS patients.

These results demonstrate that CPAP and carbocysteine might improve symptoms by reducing oxidative stress in OSAS. Upper airway dilation is closely related to OSAS severity. Pharyngeal dilator muscles may weaken or loosen as a result of increased upper airway resistance [22]. We believe that antioxidants can strengthen the tone of the upper airway dilator muscles by enhancing hypoglossal nerve activity. More importantly, antioxidants can reduce soft tissue edema in the upper airway by attenuating oxidative stress in the tissue. Carbocysteine improves the OSAS symptoms caused by both of these factors.

The main mechanism of cardiovascular disease is endothelial dysfunction [30], which is considered a subclinical indicator of vascular or myocardial dysfunction prior to the emergence of clinical signs of overt cardiovascular disease. Previous studies have shown that CPAP treatment results in an increase in NO levels [31]. However, the relationship between OSAS and ET-1, one of the most potent vasoconstriction peptides, is controversial. The plasma ET-1 level is higher in OSAS patients [32]. However, after adjustments for age, sex, oxygen saturation,

and cardiovascular disease, the plasma ET-1 level has not been shown to significantly differ between OSAS patients and controls [33]. Our study found that CPAP, but not carbocysteine, leads to a decrease in the ET-1 level. Moreover, CPAP improves endothelial function more efficiently than carbocysteine. We believe that CPAP radically reopens the upper airway, which aids in the recovery of endothelial function by ameliorating respiratory events at night. Although carbocysteine cannot completely reverse the effects of a narrow upper airway, it can effectively reduce oxidative stress, which might prevent cardiovascular complications. And we speculated that CPAP plus antioxidant carbocysteine treatment may be more effective in patients with OSAS.

Ultrasound imaging can provide both structural and functional information about superficial arteries for the direct investigation of endothelial function. FMD and IMT are often assessed in the early detection of vascular disease [34]. Previous investigations have shown that FMD is significantly correlated with atherosclerosis and that this correlation can serve as a non-invasive means of assessing vascular endothelial function [35]. Susie has found that FMD is impaired in OSAS patients compared with controls, even after adjustments for age and BMI [36]. Three months of CPAP treatment has been demonstrated to improve FMD [37]. Other studies have found that antioxidants, such as allopurinol and vitamin C, exerted similar effects [12, 13]. Our study found that carbocysteine improved FMD to a non-significant degree. This lack of significance may have been related to the study's small sample size. More importantly, a longer treatment time may be required to achieve significant improvements in FMD because changes in the biomarker levels in the body are evident prior to changes in vascular morphology. IMT can be used as an index of systemic atherosclerosis of the carotid arteries, which are the most commonly affected vessels. Ciccone found a positive correlation between IMT and OSAS severity [38]. Reductions in IMT primarily occur during the first 6 months and are sustained for 12 months in patients with reasonable CPAP compliance[39]. Our study revealed that carbocysteine reduced the IMT compared with the baseline value (0.71 ± 0.15 vs. 0.66 ± 0.15 mm). A meta-analysis has shown that a 0.1-mm increase in IMT increases the risk of stroke by 17% and increases the risk of myocardial infarction by 15% [40]. Thus, a 0.05-mm decrease in IMT may reduce the risk of future cardiovascular events after oral carbocysteine treatment. Furthermore, in OSAS patients, baseline IMT has been found to be correlated with nocturnal desaturation but not with the AHI. These results are similar to those of Takahiro's investigation [41]. We believe that OSAS patients who experience nocturnal desaturation suffer from reduced endothelial function. Additionally, IMT was found to be negatively correlated with the NO level. A reduction in the NO level may result in poor vasomotor dysfunction, increased vascular tension, blood coagulation, and a higher risk of thrombogenesis. All of the above factors highlight the occurrence and development of atherosclerosis, which causes IMT thickening.

In conclusion, the results of our study show that repeated episodes of apnea in OSAS result in oxidative stress. Oxidative stress leads to endothelial dysfunction, which can cause cardio-cerebrovascular complications and exacerbate upper airway obstruction, which creates a vicious cycle. The antioxidant carbocysteine can interrupt this cycle to some extent and improve OSAS severity while reducing cardiovascular complications. Furthermore, oral carbocysteine is safe and inexpensive. However, it cannot fundamentally reverse airway obstruction. In addition, the patients in this study did not show clinically relevant attenuation of the PSG parameters, and they remained within the severe OSAS spectrum after undergoing carbocysteine treatment. These patients continued to suffer from intermittent hypoxia. Thus, carbocysteine should only be used as an alternative treatment for OSAS patients who show poor compliance with CPAP treatment.

Limitations

Many factors affect snoring characteristics, such as the predominant site of upper airway narrowing, the route of the breath, body position, and sleep stage. However, our study used a self-controlled design, and the random selection of steady snoring episodes could have reduced the effects of these factors. The sample sizes used in this study were relatively small. Further trials involving larger populations are required to confirm our results. Moreover, only males were included, which is an additional limitation. Furthermore, few potential consequences of OSAS, such as decreased endothelial function, were evaluated. Further studies should examine whether several other morbidities that are associated with OSAS and may be effectively treated with CPAP may also benefit from antioxidant treatment. In addition, the benefits of long-term carbocysteine treatment in OSAS need to be assessed. The effects of the combined use of antioxidants and CPAP on OSAS treatment efficacy must also be examined. Furthermore, the OSAS severity level that is the most suitable for antioxidant treatment and the optimum duration of carbocysteine treatment must be determined in future studies.

Supporting Information

S1 CONSORT Checklist. CONSORT Checklist.
(DOC)

S1 Protocol. Study protocol.
(DOCX)

Acknowledgments

Author Contributions

References

1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993; 328: 1230–5. PMID: 8464434

2. Jurkovicova I, Celec P. Sleep apnea syndrome and its complications. Acta Med Austriaca. 2004; 31: 45–50. PMID: 15359982

3. Yang Q, Phillips CL, Melehan KL, Rogers NL, Seale JP, Grunstein RR. Effects of short-term CPAP withdrawal on neurobehavioral performance in patients with obstructive sleep apnea. Sleep. 2006; 29: 545–52. PMID: 16676788

4. Hedner J, Darpo B, Ejnell H, Carlson J, Caidahl K. Reduction in sympathetic activity after long-term CPAP treatment in sleep apnoea: cardiovascular implications. Eur Respir J. 1995; 8: 222–9. PMID: 7758555

5. Stepnowsky CJ, Moore PJ. Nasal CPAP treatment for obstructive sleep apnea: developing a new perspective on dosing strategies and compliance. J Psychosom Res. 2003; 54: 599–605. PMID: 12781315

6. Evans MD, Cooke MS. Factors contributing to the outcome of oxidative damage to nucleic acids. Bioessays. 2004; 26: 533–42. PMID: 15112233

7. Lavie L. Oxidative stress inflammation and endothelial dysfunction in obstructive sleep apnea. Front Biosci (Elite Ed). 2012; 4: 1391–403.

8. Lavie L. Obstructive sleep apnoea syndrome—an oxidative stress disorder. Sleep Med Rev. 2003; 7: 35–51. PMID: 12586529

9. Barcelo A, Barbe F, de la Pena M, Vila M, Perez G, Pierola J, et al. Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. Eur Respir J. 2006; 27: 756–60. PMID: 16585082

10. Phillips CL, Yang Q, Williams A, Roth M, Yee BJ, Hedner JA, et al. The effect of short-term withdrawal from continuous positive airway pressure therapy on sympathetic activity and markers of vascular inflammation in subjects with obstructive sleep apnoea. J Sleep Res. 2007; 16: 217–25. PMID: 17542952

11. Singh TD, Patial K, Vijayan VK, Ravi K. Oxidative stress and obstructive sleep apnoea syndrome. Indian J Chest Dis Allied Sci. 2009; 51: 217–24. PMID: 20073373

12. Grebe M, Eisele HJ, Weissmann N, Schaefer C, Tillmanns H, Seeger W, et al. Antioxidant vitamin C improves endothelial function in obstructive sleep apnea. Am J Respir Crit Care Med. 2006; 173: 897–901. PMID: 16439717

13. El SA, Saliba R, Bosinski T, Grant BJ, Berbary E, Miller N. Allopurinol improves endothelial function in sleep apnoea: a randomised controlled study. Eur Respir J. 2006; 27: 997–1002. PMID: 16707395

14. Sadasivam K, Patial K, Vijayan VK, Ravi K. Anti-oxidant treatment in obstructive sleep apnoea syndrome. Indian J Chest Dis Allied Sci. 2011; 53: 153–62. PMID: 21838198

15. Guizzardi F, Rodighiero S, Binelli A, Saino S, Bononi E, Dossena S, et al. S-CMC-Lys-dependent stimulation of electrogenic glutathione secretion by human respiratory epithelium. J Mol Med (Berl). 2006; 84: 97–107.

16. Nogawa H, Ishibashi Y, Ogawa A, Masuda K, Tsubuki T, Kameda T, et al. Carbocisteine can scavenge reactive oxygen species in vitro. Respirology. 2009; 14: 53–9. doi: 10.1111/j.1440-1843.2008.01424.x PMID: 19144049

17. Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, Yang L, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008; 371: 2013–8. doi: 10.1016/S0140-6736(08)60869-7 PMID: 18555912

18. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991; 14: 540–5. PMID: 1798888

19. Fiz JA, Jane R, Sola-Soler J, Abad J, Garcia MA, Morera J. Continuous analysis and monitoring of snores and their relationship to the apnea-hypopnea index. Laryngoscope. 2010; 120: 854–62. doi: 10.1002/lary.20815 PMID: 20222022

20. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39: 257–65. PMID: 11788217

21. Hashimoto M, Eto M, Akishita M, Kozaki K, Ako J, Iijima K, et al. Correlation between flow-mediated vasodilatation of the brachial artery and intima-media thickness in the carotid artery in men. Arterioscler Thromb Vasc Biol. 1999; 19: 2795–800. PMID: 10559028

22. Remmers JE, DeGroot WJ, Sauerland EK, Anch AM. Pathogenesis of upper airway occlusion during sleep. J Appl Physiol Respir Environ Exerc Physiol. 1978; 44: 931–8. PMID: 670014

23. Veasey SC, Zhan G, Fenik P, Pratico D. Long-term intermittent hypoxia: reduced excitatory hypoglossal nerve output. Am J Respir Crit Care Med. 2004; 170: 665–72. PMID: 15229096

24. Dunleavy M, Bradford A, O'Halloran KD. Oxidative stress impairs upper airway muscle endurance in an animal model of sleep-disordered breathing. Adv Exp Med Biol. 2008; 605: 458–62. PMID: 18085317

25. Hatipoglu U, Rubinstein I. Inflammation and obstructive sleep apnea syndrome pathogenesis: a working hypothesis. Respiration. 2003; 70: 665–71. PMID: 14732803

26. Jurado-Gamez B, Fernandez-Marin MC, Gomez-Chaparro JL, Munoz-Cabrera L, Lopez-Barea J, Perez-Jimenez F, et al. Relationship of oxidative stress and endothelial dysfunction in sleep apnoea. Eur Respir J. 2011; 37: 873–9. doi: 10.1183/09031936.00027910 PMID: 20650989

27. Kakkar RK, Berry RB. Positive airway pressure treatment for obstructive sleep apnea. Chest. 2007; 132: 1057–72. PMID: 17873201

28. Sola-Soler J, Fiz JA, Morera J, Jane R. Multiclass classification of subjects with sleep apnoea-hypopnoea syndrome through snoring analysis. Med Eng Phys. 2012; 34: 1213–20. doi: 10.1016/j.medengphy.2011.12.008 PMID: 22226588

29. Lei X, Xingjian H, Weiwei G. Research and application of polylines capacitance algorithm in the snoring recognition. Electronic Measurement Technology. 2013; 36: 6–10.

30. Lurie A. Endothelial dysfunction in adults with obstructive sleep apnea. Adv Cardiol. 2011; 46: 139–70. doi: 10.1159/000325108 PMID: 22005191

31. Ip MS, Lam B, Chan LY, Zheng L, Tsang KW, Fung PC, et al. Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med. 2000; 162: 2166–71. PMID: 11112132

32. Phillips BG, Narkiewicz K, Pesek CA, Haynes WG, Dyken ME, Somers VK. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens. 1999; 17: 61–6. PMID: 10100095

33. Grimpen F, Kanne P, Schulz E, Hagenah G, Hasenfuss G, Andreas S. Endothelin-1 plasma levels are not elevated in patients with obstructive sleep apnoea. Eur Respir J. 2000; 15: 320–5. PMID: 10706499

34. The Cardiovascular Committee of the Chinese Association of Rehabilitation Medicine,International Society of Vascular Health. Chinese Guideline for Early Vascular Disease Detection(2011 Second Report). ADVANCES IN CARDIOVASCULAR DISEASES. 2011; 32: 318–23.

35. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340: 1111–5. PMID: 1359209

36. Yim-Yeh S, Rahangdale S, Nguyen AT, Jordan AS, Novack V, Veves A, et al. Obstructive sleep apnea and aging effects on macrovascular and microcirculatory function. Sleep. 2010; 33: 1177–83. PMID: 20857864

37. Nguyen PK, Katikireddy CK, McConnell MV, Kushida C, Yang PC. Nasal continuous positive airway pressure improves myocardial perfusion reserve and endothelial-dependent vasodilation in patients with obstructive sleep apnea. J Cardiovasc Magn Reson. 2010; 12: 50. doi: 10.1186/1532-429X-12-50 PMID: 20815898

38. Ciccone MM, Scicchitano P, Mitacchione G, Zito A, Gesualdo M, Caputo P, et al. Is there a correlation between OSAS duration/severity and carotid intima-media thickness? Respir Med. 2012; 106: 740–6. doi: 10.1016/j.rmed.2011.12.016 PMID: 22317765

39. Hui DS, Shang Q, Ko FW, Ng SS, Szeto CC, Ngai J, et al. A prospective cohort study of the long-term effects of CPAP on carotid artery intima-media thickness in obstructive sleep apnea syndrome. Respir Res. 2012; 13: 22. doi: 10.1186/1465-9921-13-22 PMID: 22424053

40. van den Oord SC, Sijbrands EJ, Ten KG, van Klaveren D, van Domburg RT, van der Steen AF et al. Carotid intima-media thickness for cardiovascular risk assessment: systematic review and meta-analysis. Atherosclerosis 2013; 228(1): 1–11. doi: 10.1016/j.atherosclerosis.2013.01.025 PMID: 23395523

41. Suzuki T, Nakano H, Maekawa J, Okamoto Y, Ohnishi Y, Yamauchi M, et al. Obstructive sleep apnea and carotid-artery intima-media thickness. Sleep. 2004; 27: 129–33. PMID: 14998249